Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josy Reiffers

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Transfusion|November 2, 2006
Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacityJean-Michel Boiron, Bernard Dazey, Christian Cailliot, et al.
Blood|May 19, 2010
Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remissionNorbert-Claude Gorin, Myriam Labopin, Josy Reiffers, et al.
Blood|March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemiaJean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
British Journal of Haematology|March 5, 2003
Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanismAnne Solanilla, Christophe Grosset, Pascale Duchez, et al.
The Lancet. Oncology|October 23, 2010
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialFrançois-Xavier Mahon, Delphine Réa, Joëlle Guilhot, et al.
Blood|September 16, 2006
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsPhilippe Rousselot, Francoise Huguet, Delphine Rea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remissionNorbert-Claude Gorin, Myriam Labopin, Didier Blaise, et al.
Blood|December 29, 2006
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaStephane Picard, Karine Titier, Gabriel Etienne, et al.
Carcinogenesis|August 2, 2002
Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cellsHélène Ferry-Dumazet, Olivier Garnier, Maria Mamani-Matsuda, et al.
American Journal of Hematology|October 9, 2014
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?Gabriel Etienne, Stéphanie Dulucq, Axelle Lascaux, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Transfusion|November 2, 2006
Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacityJean-Michel Boiron, Bernard Dazey, Christian Cailliot, et al.
Blood|May 19, 2010
Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remissionNorbert-Claude Gorin, Myriam Labopin, Josy Reiffers, et al.
Blood|March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemiaJean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
British Journal of Haematology|March 5, 2003
Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanismAnne Solanilla, Christophe Grosset, Pascale Duchez, et al.
The Lancet. Oncology|October 23, 2010
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialFrançois-Xavier Mahon, Delphine Réa, Joëlle Guilhot, et al.
Blood|September 16, 2006
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsPhilippe Rousselot, Francoise Huguet, Delphine Rea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remissionNorbert-Claude Gorin, Myriam Labopin, Didier Blaise, et al.
Blood|December 29, 2006
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaStephane Picard, Karine Titier, Gabriel Etienne, et al.
Carcinogenesis|August 2, 2002
Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cellsHélène Ferry-Dumazet, Olivier Garnier, Maria Mamani-Matsuda, et al.
American Journal of Hematology|October 9, 2014
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?Gabriel Etienne, Stéphanie Dulucq, Axelle Lascaux, et al.
Pageof 5